Biogen company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

About Biogen

Biogen is an AD operator, providing a food waste recycling service for local authorities and commercial organizations. Food waste is collected from supermarkets, restaurants, manufacturers, and households. At its AD plant, the organic matter is depackaged and processed to produce biogas. The biogas is captured and fed into super-efficient gas engines to generate renewable electricity for the grid. What remains is a biofertilizer which is put back into the land to grow more crop.

Biogen Headquarter Location

Milton Parc Milton Ernest

Bedfordshire, MK44 1YU,

United Kingdom

+44 01234827249

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Biogen

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biogen in 2 CB Insights research briefs, most recently on Aug 31, 2021.

Expert Collections containing Biogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biogen is included in 1 Expert Collection, including Smart Cities.


Smart Cities

1,145 items

Biogen Patents

Biogen has filed 480 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Immune system, Immunology, Clusters of differentiation, Monoclonal antibodies, Cell biology


Application Date


Grant Date



Related Topics

Immune system, Immunology, Clusters of differentiation, Monoclonal antibodies, Cell biology



Latest Biogen News

Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

Jun 28, 2022

Biogen and Happify Health , the Intelligent Healing Company, announce a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their well-being, learn about treatment options, consult with experts, and connect with other people in the MS community for support. “This collaboration is one of many ways we are focused on supporting patients by meeting them where they are. The combination of Biogen’s expertise in neuroscience and our commitment to digital health, along with Happify Health’s AI and digital therapeutic capabilities will help drive a connected and comprehensive experience that allows patients to feel supported throughout their journey,” said Jason Hawbecker, Head of Strategic Partnerships & Collaborations at Biogen. “We are excited about the potential of this partnership to provide overall support for the MS community.” The Happify Health solution, which brings together a digital tool configured for MS and a care community (Kopa), offers holistic health and wellness support, with access to neurology providers (doctors, nurse practitioners, physicians assistants and nurses) as well as mental health specialists, dietitians, and rehabilitation professionals. The online community that recently launched provides a place for those living with MS to ask experts questions and discuss the physical and mental challenges they are facing with patients in similar stages. Happify Health uses its proprietary AI technology to personalize content to patients’ life stages, symptoms and interests. “It can be challenging for people living with MS to stay up-to-date with the latest treatments, interpret new symptoms, or investigate changes in their health that may or may not be related to MS,” said Ofer Leidner, President of Happify Health. “We are providing the MS community with a solution configured to accommodate their specific needs, as well as opportunities to engage with experts, receive curated content, and discuss disease management with other community members. We are very excited to partner with Biogen on this opportunity given their leadership in the MS space.” Biogen will provide support for the MS platform, including educational content and resources for the patient care journey. The company is a global leader in treating MS with a portfolio of medicines to treat relapsing forms of MS, characterized by periods where symptoms subside, with full or partial recovery, and there is no disease progression between attacks. In addition to psoriasis and maternal health, MS is the third therapeutic area to be addressed through Happify Health’s unique Sequence approach. Sequences are configured to support specific medical conditions and weave together components like evidence-based digital therapeutics, online communities, and coaching in one unified platform, with recommendations tailored for each individual. [Source(s): Happify Health, Business Wire] Share: Rate:

  • When was Biogen founded?

    Biogen was founded in 2005.

  • Where is Biogen's headquarters?

    Biogen's headquarters is located at Milton Parc, Bedfordshire.

  • What is Biogen's latest funding round?

    Biogen's latest funding round is Acquired.

  • Who are the investors of Biogen?

    Investors of Biogen include Ancala Partners.

  • Who are Biogen's competitors?

    Competitors of Biogen include Healios.

You May Also Like

Biofourmis Logo

Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology for pharmaceutical companies to demonstrate value, and cost-effective solutions for payers. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. The company was founded in 2015 and is based in Boston, Massachusetts.


Healios provides patients and doctors with mobile health platforms and Digital Biomarkers to improve patient diagnosis and treatment, research and clinical practice.

Roche Holding Logo
Roche Holding

Roche Holding is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

Helius Medical Technologies

Helius Medical Technologies is the medical device holding company in the business of innovation. The company's primary asset is NeuroHabilitation's PoNS device being developed for treatment of neurological symptoms caused by disease or trauma.

Novartis Logo

Novartis (NYSE: NVS) is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Focusing solely on healthcare, Novartis offers a diversified portfolio to meet these needs including medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products.

Genentech Logo

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.